Stoke Therapeutics, Inc. (STOK) is a biotechnology company focused on developing innovative treatments for genetic diseases.
Their primary aim is to address severe genetic disorders by upregulating protein expression using their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform allows Stoke to precisely increase the production of proteins that are deficient due to genetic mutations. Their lead product candidate, STK-001, targets Dravet syndrome, a severe and life-threatening form of epilepsy.
By increasing the expression of the healthy copy of the SCN1A gene, STK-001 aims to reduce the frequency and severity of seizures in patients. Stoke Therapeutics is also exploring treatments for other genetic diseases with similar approaches. The company’s growth is driven by the urgent need for effective therapies for rare genetic conditions, which often have limited or no treatment options.
Stoke’s cutting-edge technology and focus on unmet medical needs position them well in the biopharmaceutical industry. Their strong pipeline, promising clinical data, and strategic collaborations with research institutions and pharmaceutical companies further support their growth trajectory. As they advance their clinical programs and expand their therapeutic applications, Stoke Therapeutics continues to make significant strides towards improving the lives of patients with genetic disorders.
